Schering gets EU nod for PET (positron emission tomography) cancer agent:
This article was originally published in Clinica
Schering has gained the go-ahead in Europe to market its positron emission tomography (PET) imaging agent, Flucis, for diagnosing cancer. The agent, which can also help doctors monitor, stage and detect disease recurrence, has several indications, including head and neck cancer, lung cancer and malignant lymphomas. Other indications include the staging and detection of recurrences from colorectal cancer and melanoma.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.